导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.84% | 969/4773 |
| 近一周 | -1.32% | 2022/5465 |
| 近一月 | -2.29% | 1561/5421 |
| 近一季 | -7.73% | 2946/5231 |
| 近半年 | -0.95% | 1634/4920 |
| 近一年 | 11.61% | 1010/4394 |
| 近两年 | 84.02% | 796/2954 |
| 近三年 | 48.87% | 580/2253 |
| 成立以来 | 42.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.37% 954/4961 |
21.25% 1183/5312 |
- - |
- - |
| 2025 | 30.75% 1294/4813 |
6.00% 694/3635 |
3.85% 935/4076 |
18.25% 2321/4524 |
0.44% 1997/4813 |
| 2024 | 10.75% 1381/3463 |
-1.79% 1279/2808 |
-2.47% 1193/3014 |
11.60% 2493/3129 |
3.60% 791/3463 |
| 2023 | -0.10% 434/2656 |
8.27% 474/2280 |
-1.25% 460/2385 |
-1.50% 531/2515 |
-5.14% 1268/2655 |
| 2022 | -19.71% 886/2207 |
-11.83% 546/1919 |
3.67% 1112/2016 |
-9.03% 238/2113 |
-3.44% 1850/2208 |
| 2021 | -2.27% 843/1822 |
-5.75% 954/1255 |
11.73% 363/1330 |
-8.30% 1124/1466 |
1.21% 985/1822 |
| 2020 | 20.33% 719/1250 |
-5.29% 406/1028 |
23.58% 192/1067 |
0.66% 1040/1164 |
2.14% 1008/1184 |
| 2019 | 35.32% 379/1092 |
25.86% 442/754 |
-5.25% 462/804 |
4.26% 209/850 |
8.84% 279/918 |
| 2018 | -28.39% 441/834 |
- - |
- - |
- - |
-13.24% 519/691 |
| 2017 | 12.44% 276/714 |
- - |
- - |
- - |
- - |
| 2016 | 2.36% 83/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 博时中证淘金大数据100I VS. 长安沪深300非周期A(740101) |